{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-041321","form_type":"8-K","ticker":null,"cik":"0001429560","company_name":"TREVENA INC","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.379420+00:00","generated_at":"2026-06-04T04:26:23.627830+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Trevena Q4 net loss $16.5M; reduces OLINVYK support, reviews alternatives","bullets":["Net loss $16.5M ($1.06/share) vs $7.0M ($0.73/share) in Q4 2022.","FY2023 net loss $40.3M ($3.16/share); cash $33.0M as of Dec 31, 2023.","Reducing OLINVYK commercial support; reviewing strategic alternatives including sale or license.","TRV045 advances toward Phase 2 readiness with positive PoC data in neuropathic pain and epilepsy.","TRV045 showed no lymphopenia, bradycardia, or BP changes vs other S1P modulators."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-041321","json":"https://secwatch.observer/filing/0001104659-24-041321.json","markdown":"https://secwatch.observer/filing/0001104659-24-041321.md","text":"https://secwatch.observer/filing/0001104659-24-041321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429560/000110465924041321/0001104659-24-041321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429560/000110465924041321/tm2410264d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:26:23.627830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"de8628a18606791ecf343bdf81c3872e3250842a","claim":"TREVENA INC reported fourth quarter ended December 31, 2023 results: net income $16.5 million, EPS $1.06 per share.","evidence_excerpt":"For the fourth quarter of 2023, the Company reported a net loss attributable to common stockholders of $16.5 million, or $1.06 per share, compared to $7.0 million, or $0.73 per share in the fourth quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429560/000110465924041321/0001104659-24-041321-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2023"},{"label":"Net income","value":"$16.5 million"},{"label":"EPS","value":"$1.06 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"eef0cbf0c11fca7087b71d8e4b412bb166ceb59d","claim":"TREVENA INC reported full year ended December 31, 2023 results: net income $40.3 million, EPS $3.16 per share.","evidence_excerpt":"For the full year ended December 31, 2023, net loss attributable to common stockholders was $40.3 million, or $3.16 per share, compared to $53.7 million, or $7.59 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429560/000110465924041321/0001104659-24-041321-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2023"},{"label":"Net income","value":"$40.3 million"},{"label":"EPS","value":"$3.16 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}